Evotec SE (0IRF.IL)
- EQS Group
Evotec SE to announce preliminary financial results for fiscal year 2022 on 28 March 2023
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec SE to announce preliminary financial results for fiscal year 2022 on 28 March 2023 21.03.2023 / 11:50 CET/CESTThe issuer is solely responsible for the content of this announcement.Hamburg, Germany, 21 March 2023:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its preliminary financial results for 2022 on Tuesday, 28 March 2023.The Company is going to hold a conference call to discuss the
- EQS Group
Evotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb 16.03.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. KEY SCIENTIFIC ACHIEVEMENTS DRIVE THE EXPANSION OF THE PIPELINE OF MOLECULAR GLUE DEGRADERS PERFORMANCE-BASED AND PROGRAMME-BASED PAYMENTS OF IN TOTAL US$ 75 M TO EVOTECHamburg, Germany, 16 March 2023:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, I
- EQS Group
Evotec receives € 150 m loan from European Investment Bank
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec receives € 150 m loan from European Investment Bank 10.02.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. FINANCING FOR 3 CORE PILLARS: R&D ACTIVITIES, EQUITY INVESTMENTS AND CONSTRUCTION OF MANUFACTURING FACILITY DEDICATED TO BIOLOGICS, J.POD® TOULOUSE, FRANCE (EU) FOLLOW-ON TO THE EXISTING € 75 M LOAN FACILITY FROM 2017 UNSECURED LOAN FACILITY TAILORED TO STRATEGIC PLANS OF EVOTEC TRANSACTION TO
